421
Views
13
CrossRef citations to date
0
Altmetric
Special Report

The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors

, , , , , , , , , , & show all

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Eleonora Lai, Andrea Pretta, Valentino Impera, Stefano Mariani, Riccardo Giampieri, Laura Casula, Valeria Pusceddu, Pierpaolo Coni, Daniela Fanni, Marco Puzzoni, Laura Demurtas, Pina Ziranu, Gavino Faa & Mario Scartozzi. (2018) BRAF-mutant colorectal cancer, a different breed evolving. Expert Review of Molecular Diagnostics 18:6, pages 499-512.
Read now

Articles from other publishers (12)

Paweł M. Potocki, Piotr Wójcik, Łukasz Chmura, Bartłomiej Goc, Marcin Fedewicz, Zofia Bielańska, Jakub Swadźba, Kamil Konopka, Łukasz Kwinta & Piotr J. Wysocki. (2023) Clinical Characterization of Targetable Mutations (BRAF V600E and KRAS G12C) in Advanced Colorectal Cancer—A Nation-Wide Study. International Journal of Molecular Sciences 24:10, pages 9073.
Crossref
Eleonora Lai, Stefano Cascinu & Mario Scartozzi. (2021) Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice. Frontiers in Oncology 11.
Crossref
Vanessa Wong, Margaret Lee, Rachel Wong, Jeanne Tie, Jeremy Shapiro, Jayesh Desai, Louise Nott, Simone Steel, Matthew Burge, Brigette Ma, Adnan Khattak, Wei Hong & Peter Gibbs. (2021) BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?. Targeted Oncology 16:2, pages 227-236.
Crossref
Carolina Bernabe-Ramirez, Rajvi Patel, Jaspreet Chahal & Muhammad Wasif Saif. (2020) Treatment options in BRAF-mutant metastatic colorectal cancer. Anti-Cancer Drugs 31:6, pages 545-557.
Crossref
Marco Puzzoni, Pina Ziranu, Laura Demurtas, Eleonora Lai, Stefano Mariani, Nicole Liscia, Paolo Soro, Andrea Pretta, Valentino Impera, Silvia Camera, Francesca Musio, Mara Persano, Clelia Donisi, Simona Tolu, Francesca Balconi & Mario Scartozzi. (2020) Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients. Future Oncology 16:2, pages 4337-4339.
Crossref
Melissa W. Taggart, Wai Chin Foo & Sun Mi Lee. 2020. Oncological Surgical Pathology. Oncological Surgical Pathology 691 870 .
Kristen K. Ciombor & Tanios Bekaii-Saab. (2018) A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. The Oncologist 23:1, pages 25-34.
Crossref
Yasar Subutay Peker, Mehmet Fatih Can, Ismail Hakki Ozerhan, Gokhan Yagci, Nazif Zeybek, Kutan Kavakli, Sedat Gurkok, Alper Gozubuyuk, Onur Genc, Gokhan Erdem, Ahmet Ozet, Mustafa Gerek & Yusuf Peker. (2018) BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report. Case Reports in Surgery 2018, pages 1-6.
Crossref
John H. Strickler, Christina Wu & Tanios Bekaii-Saab. (2017) Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. Cancer Treatment Reviews 60, pages 109-119.
Crossref
Giuseppe Aprile, Mariaelena Casagrande, Giovanna De Maglio, Caterina Fontanella, Karim Rihawi, Marta Bonotto, Federica E Pisa, Francesco Tuniz, Stefano Pizzolitto & Gianpiero Fasola. (2017) Comparison of the molecular profile of brain metastases from colorectal cancer and corresponding primary tumors. Future Oncology 13:2, pages 135-144.
Crossref
Paulo Matos, Vânia Gonçalves & Peter Jordan. (2016) Targeting the serrated pathway of colorectal cancer with mutation in BRAF. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1866:1, pages 51-63.
Crossref
Michael J. Schwerer, Julia Boehmer, Matthias Graw & Florian Fischer. (2015) Comparison of DNA preparation results from autopsy tissue specimens with or without previous postmortal CT angiography. Forensic Science International: Genetics Supplement Series 5, pages e662-e663.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.